GlassScriptPhysician profile
Samreen Rizvi Raza
NPI 1205135985
$5,608.53
in general payments reported to CMS, 2019-2025
27 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,584 · 2020: $291 · 2021: $993 · 2022: $452 · 2023: $525 · 2024: $617 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,802.46 | 2019-2024 | |
| Abbott Laboratories | $600.53 | 2019-2025 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $570.21 | 2019-2025 | Ffrct |
| Ge Healthcare | $550.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.98 | 2019-2024 | Lifevest |
| Amgen INC. | $349.64 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $158.87 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $125.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.14 | 2022-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $117.53 | 2022-2024 | Barostim Neo System |
| Irhythm Technologies, INC. | $114.44 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $107.36 | 2020-2022 | |
| Pfizer INC. | $85.20 | 2019-2022 | |
| Novo Nordisk INC | $81.24 | 2023-2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $66.62 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $55.51 | 2025 | |
| Philips North America LLC | $54.56 | 2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $51.98 | 2020-2021 | |
| Innovation Technologies INC | $49.80 | 2022 | |
| Merck Sharp & Dohme LLC | $30.06 | 2021 | |
| Kestra Medical Technology Services, INC. | $28.94 | 2024 | Assure Wcd |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.90 | 2024 | Rexulti |
| Boston Scientific Corporation | $23.92 | 2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $20.85 | 2021 | |
| Portola Pharmaceuticals, LLC | $20.77 | 2019 | |
| Vital Connect, INC | $17.64 | 2023 | Vitalpatch Rtm |
| Siemens Medical Solutions USA, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samreen Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.